ScreenerHero

XGN Exagen Inc.

NAS · US · Healthcare · Diagnostics & Research · exagen.com
8.300USD+1.34%Mkt Cap: 201.07M $P/E: —

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and m…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$244.79BUSDP/E 36.7
DHR
Danaher Corporation
$153.60BUSDP/E 38.9
NTRA
Natera, Inc.
$57.02BUSD
LONN
Lonza Group AG
$46.01BUSDP/E 38.3
A
Agilent Technologies, Inc.
$47.67BUSDP/E 33.4
WAT
Waters Corporation
$42.81BUSDP/E 110.4
IQV
IQVIA Holdings Inc.
$42.48BUSDP/E 32.1
ILMN
Illumina, Inc.
$40.43BUSDP/E 50.0
IDXX
IDEXX Laboratories, Inc.
$39.97BUSDP/E 35.6
MTD
Mettler-Toledo International Inc.
$30.73BUSDP/E 34.6
LH
Labcorp Holdings Inc.
$25.30BUSDP/E 25.8
DGX
Quest Diagnostics Incorporated
$25.06BUSDP/E 24.1
GH
Guardant Health, Inc.
$22.59BUSD
RVTY
Revvity, Inc.
$17.14BUSDP/E 73.5
MEDP
Medpace Holdings, Inc.
$16.87BUSDP/E 35.5
ERF
Eurofins Scientific SE
$14.23BUSDP/E 26.6
CRL
Charles River Laboratories International, Inc.
$14.34BUSD
ICLR
ICON Public Limited Company
$12.66BUSDP/E 172.7
BIM
bioMérieux S.A.
$10.35BUSDP/E 20.7
QGEN
Qiagen N.V.
$9.25BUSDP/E 22.7

Key Statistics

Company
Market Cap201.07M USD
Enterprise Value201.47M USD
Revenue (TTM)71.12M USD
Gross Profit38.80M USD
Net Income (TTM)-19.95M USD
Revenue/Share3.01 USD
Last Price8.300 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees216
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.43
PEG—
EV/EBITDA-18.70
EV/Revenue2.83
P/S2.79
P/B16.22
EPS (TTM)-0.78
EPS (Forward)-0.47
52W Range
2.59059% of range12.23
52W High12.23 USD
52W Low2.590 USD
Profitability
Gross Margin58.28%
Oper. Margin-8.63%
EBITDA Margin-15.15%
Profit Margin-29.97%
ROE-114.34%
ROA-34.39%
Growth
Revenue Growth15.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.63M USD
CapEx (TTM)641.00K USD
FCF Margin-2.19%
FCF Yield-0.77%
Net Debt3.07M USD
Net Debt/EBITDA-0.28
Balance Sheet
Debt/Equity1.47
Current Ratio3.19
Quick Ratio2.75
Book Value/Sh0.51 USD
Cash/Share1.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.14 USD
Upside (mean)+22.2%
Target Range9.000 USD – 12.00 USD
9.000+22.2% to mean12.00
# Analysts7
Ownership
Shares Out.24.23M
Float13.84M
Insiders24.33%
Institutions44.89%
Short Interest
Short Ratio2.8d
Short % Float3.65%
Short % Out.3.30%
Shares Short800.34K
Short (prev mo.)940.43K
Technical
SMA 507.171 (+15.8%)
SMA 2004.839 (+71.5%)
Beta2.12
S&P 52W Chg16.45%
Avg Vol (30d)302.15K
Avg Vol (10d)324.54K
Technical Indicators
RSI (14)58.4
MACD0.3718
MACD Signal0.4612
MACD Hist.-0.0894
BB Upper9.251 USD
BB Middle8.057 USD
BB Lower6.864 USD
BB Width29.63%
ATR (14)0.4439 USD
Vol Ratio (20d)0.80x